Is there something GLP-1s can’t do? Diabetes and weight problems are more and more wanting just like the tip of the semaglutide iceberg. The Meals and Drug Administration (FDA) has permitted Wegovy for heart problems, and researchers are actually exploring the potential of GLP-1s for a bunch of circumstances, together with bronchial asthma, arthritis and psoriasis, sure liver illnesses, despair, eye problems, Alzheimer’s, and substance use problems. A current examine even discovered GLP-1s might cut back the chance of 10 totally different cancers.
The rising checklist of potential GLP-1 indications suggests the medication might goal the foundation trigger (irritation, in all probability) of essentially the most prevalent and expensive circumstances within the U.S. If even a fraction of the trials now underway pan out, GLP-1s have the potential to reshape well being care as we all know it.
However they will’t remedy the whole lot. In reality, the GLP-1 phenomenon is making the fragmentation and dysfunction of our well being care system much more obvious. Simply as GLP-1s might assist us uncover the frequent denominator in seemingly disparate illnesses, they’re shining a brilliant gentle on the foundation causes of the well being care system’s ills.
Medicine are too costly
The value tag of GLP-1s within the U.S.—as much as $15,000 per yr, far greater than in different prosperous international locations—has grow to be one of many single largest drivers of rising well being care prices. Non-public employers, already going through an unsustainable value development, are feeling the strain from their workforce to cowl the medication, but they fairly actually might not be capable to afford it. Some research recommend widespread GLP-1 adoption, absent value controls, may bankrupt Medicare and the well being care system as a complete.
GLP-1s are additionally shining a harsh gentle on the inefficiency and inequity in well being care. Those that can afford to pay out of pocket are gobbling up the availability of GLP-1s (in some instances for self-importance use), whereas entry stays restricted for individuals on Medicare or Medicaid who’re disproportionately burdened by weight problems and diabetes. For instance, Eli Lilly’s current transfer to slash the worth of Zepbound solely applies to sufferers paying out of pocket; and at a number of hundred {dollars} monthly, even the markdown worth is out of attain for a lot of.
GLP-1s reveals how shortly well being care can flip right into a gold rush
Pharmaceutical firms, telehealth suppliers, and even complement sellers are advertising GLP-1s on to shoppers to fulfill the runaway demand. Exploiting a loophole ensuing from the GLP-1 scarcity, some suppliers are prescribing compounded generic variations of the medication that the FDA has warned could also be unsafe.
It is a prime instance of the restrictions of the transactional Telehealth 1.0 mannequin and the risks of consumerism operating amok. Sufferers can simply get compounded GLP-1s, even when life-style adjustments or different approaches are extra clinically applicable. However who’s taking care of their well being as soon as the transaction is full? Who helps them handle unintended effects, in addition to their general bodily and psychological well being?
If sufferers get sick from compounded GLP-1s, they might find yourself within the ER—and their employer and insurer foot the invoice. On this state of affairs, nobody wins.
Fragmented care supply
The kind of clinicians prescribing GLP-1s has expanded quickly. Of their first act as a diabetes drug, GLP-1s had been prescribed nearly solely by endocrinologists. Now cardiologists, orthopedists, inner medication physicians, and even psychiatrists are prescribing them—presumably with a unique lens than an endocrinologist would, and generally with out full visibility into the affected person’s general well being. Completely different specialties are beginning to set up their very own scientific pointers for GLP-1s.
Given how siloed specialty care is, it’s more and more possible {that a} main care doctor (PCP) may prescribe GLP-1s for weight administration with out the affected person’s heart specialist realizing about it—and vice versa. Who’s looking for the entire individual? Who’s taking a look at scientific outcomes and prices in a holistic means—for that affected person, and for the system as a complete?
The prescription we actually want
I’m rooting for GLP-1s to be a miracle drug. However the jury remains to be out, and within the meantime, the GLP-1 frenzy is exposing healthcare stakeholders throughout the system—sufferers, employers, insurers, suppliers—to unsustainable scientific and monetary dangers.
On the plus facet, these mounting dangers—and the unprecedented consideration from shoppers and the trade alike—might lastly be what it takes to repair damaged well being care fashions. And the options to the issues surrounding GLP-1s are the identical ones we’ve wanted all alongside:
- Prevention. The U.S. invests far much less in preventive and first care than different prosperous nations. Growing entry to main care and psychological well being providers—together with by way of digital care—is important to sustainably handle the upstream causes of the circumstances we’re now treating with GLP-1s.
- Built-in care. This contains longitudinal care coordination between PCPs and specialists, in addition to navigators and affected person advocates. The wrap-around monetary and administrative help these care group members present is very vital given the excessive value of the medication and the challenges of managing persistent circumstances like diabetes.
- Outcomes-based fee. The current push to incorporate GLP-1s in Medicare negotiations is an efficient begin, however it’s not a silver bullet for the healthcare value development. Regardless of the buyer demand for GLP-1s, research have proven that as many as two-thirds of sufferers don’t follow the medication lengthy sufficient to realize or maintain the scientific advantages, which implies substantial upfront prices with little to no payoff for sufferers and healthcare purchasers. Enterprise and fee fashions tied to scientific and monetary outcomes that matter—and that incentivize considered prescribing and the built-in care wanted to spice up adherence and long-term outcomes—are a essential step towards minimizing waste and realizing the complete worth of GLP-1s.
GLP-1s have the potential to remodel medication. But when we proceed shoehorning them into our siloed and fragmented well being care system, their potential will probably be stunted. It’s yet one more indication that we have to reimagine the well being care system from the bottom up.
Extra must-read commentary revealed by Fortune:
The opinions expressed in Fortune.com commentary items are solely the views of their authors and don’t essentially mirror the opinions and beliefs of Fortune.
